Cargando…
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the eviden...
Autores principales: | García-Casares, Natalia, González-González, Guillermo, de la Cruz-Cosme, Carlos, Garzón-Maldonado, Francisco J, de Rojas-Leal, Carmen, Ariza, María J, Narváez, Manuel, Barbancho, Miguel Ángel, García-Arnés, Juan Antonio, Tinahones, Francisco J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404567/ https://www.ncbi.nlm.nih.gov/pubmed/37231200 http://dx.doi.org/10.1007/s11154-023-09807-3 |
Ejemplares similares
-
Intranasal Delivery of Galanin 2 and Neuropeptide Y1 Agonists Enhanced Spatial Memory Performance and Neuronal Precursor Cells Proliferation in the Dorsal Hippocampus in Rats
por: Borroto-Escuela, Dasiel O., et al.
Publicado: (2022) -
FRI652 Type 2 Diabetes Management: More GLP1 Agonists And Less Metformin?
por: Lopez Maldonado, Francisco J, et al.
Publicado: (2023) -
Evidence of Animal-Assisted Therapy in Neurological Diseases in Adults: A Systematic Review
por: Rodríguez-Martínez, María del Carmen, et al.
Publicado: (2021) -
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018) -
The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)